Education
About Us
Working with TipRanks
Follow Us
GeneDx Holdings (WGS)
NASDAQ:WGS
WGS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.72 - $115.60
Previous CloseN/A
Volume338.68K
Average Volume (3M)1.29M
Market Cap
$2.52B
Enterprise Value$1.15B
Total Cash (Recent Filing)$85.21M
Total Debt (Recent Filing)$64.25M
Price to Earnings (P/E)38.8
Beta1.55
Next Earnings
May 07, 2025EPS Estimate
0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.99
Shares Outstanding28,068,274
10 Day Avg. Volume938,284
30 Day Avg. Volume1,289,368
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.01
Price to Cash Flow (P/CF)-216.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.46
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.92
Enterprise Value/Ebitda-38.27
Forecast
1Y Price Target
$113.00Price Target Upside26.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceGeneDx delivered on its goal of GAAP profitability, ahead of expectations, with an adjusted net income of $17M in the fourth quarter.
Market Growth PotentialWith only about 5% of the total addressable market penetrated, earnings and free cash flow are inflecting, suggesting more growth potential.
Bears Say
Reputation ChallengesA short report alleges wholesale reimbursement fraud at GeneDx, which led to a decrease in the company's shares.
---
Ownership Overview
61.77% Insiders
4.65% Mutual Funds
1.03% Other Institutional Investors
26.40% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
WGS FAQ
What was GeneDx Holdings’s price range in the past 12 months?
GeneDx Holdings lowest stock price was $7.72 and its highest was $115.60 in the past 12 months.
What is GeneDx Holdings’s market cap?
GeneDx Holdings’s market cap is $2.52B.
When is GeneDx Holdings’s upcoming earnings report date?
GeneDx Holdings’s upcoming earnings report date is May 07, 2025 which is in 56 days.
How were GeneDx Holdings’s earnings last quarter?
GeneDx Holdings released its earnings results on Feb 18, 2025. The company reported $0.771 earnings per share for the quarter, beating the consensus estimate of $0.163 by $0.608.
Is GeneDx Holdings overvalued?
According to Wall Street analysts GeneDx Holdings’s price is currently Undervalued.
Does GeneDx Holdings pay dividends?
GeneDx Holdings does not currently pay dividends.
What is GeneDx Holdings’s EPS estimate?
GeneDx Holdings’s EPS estimate is 0.08.
How many shares outstanding does GeneDx Holdings have?
GeneDx Holdings has 28,068,274 shares outstanding.
What happened to GeneDx Holdings’s price movement after its last earnings report?
GeneDx Holdings reported an EPS of $0.771 in its last earnings report, beating expectations of $0.163. Following the earnings report the stock price went up 47.688%.
Which hedge fund is a major shareholder of GeneDx Holdings?
Currently, no hedge funds are holding shares in WGS
---
GeneDx Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$113.00 (26.03% Upside)
$113.00 (26.03% Upside)
Blogger Sentiment
Bullish
WGS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 444.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 2.2%
Last 30 Days ▼ 6.6%
Last 30 Days ▼ 6.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
968.65%
12-Months-Change
Fundamentals
Return on Equity
-22.10%
Trailing 12-Months
Asset Growth
-1.89%
Trailing 12-Months
Company Description
GeneDx Holdings
CM Life Sciences Inc is a blank check company.
---
WGS Company Deck
---
WGS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
GeneDx reported strong financial performance with significant revenue and margin growth driven by the success of their exome and genome testing. They are making strategic investments to fuel future growth, including expanding their sales force and launching new products. However, challenges remain with high denial rates on test reimbursements and the decision to exit the hereditary cancer segment.Read More>---
WGS Revenue Breakdown
96.59% Diagnostic test revenue
3.41% Other
---
WGS Stock 12 Month Forecast
Average Price Target
$113.00
▲(26.03% Upside)
Technical Analysis
Best Analysts Covering WGS
1 Year
1 Year Success Rate
11/19 ratings generated profit
1 Year Average Return
+165.57%
reiterated a buy rating 17 days ago
Copying Mark Massaro's trades and holding each position for 1 Year would result in 57.89% of your transactions generating a profit, with an average return of +165.57% per trade.
---